91 related articles for article (PubMed ID: 12780786)
21. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
22. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Wang ZD; Li D; Huang XJ
Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
[TBL] [Abstract][Full Text] [Related]
23. Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia).
Halder TM; Blüggel M; Heinzel S; Pawelec G; Meyer HE; Kalbacher H
Blood; 2000 May; 95(9):2890-6. PubMed ID: 10779436
[TBL] [Abstract][Full Text] [Related]
24. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions.
Datta AR; Barrett AJ; Jiang YZ; Guimarães A; Mavroudis DA; van Rhee F; Gordon AA; Madrigal A
Bone Marrow Transplant; 1994 Oct; 14(4):517-24. PubMed ID: 7858526
[TBL] [Abstract][Full Text] [Related]
25. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
26. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
27. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
28. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells.
von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH
Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495
[TBL] [Abstract][Full Text] [Related]
29. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect.
Dodi IA; Van Rhee F; Forde HC; Roura-Mir C; Jaraquemada D; Goldman JM; Madrigal JA
Cytotherapy; 2002; 4(4):353-63. PubMed ID: 12396836
[TBL] [Abstract][Full Text] [Related]
30. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.
Marijt WA; Kernan NA; Diaz-Barrientos T; Veenhof WF; O'Reilly RJ; Willemze R; Falkenburg JH
Bone Marrow Transplant; 1995 Jul; 16(1):125-32. PubMed ID: 7581111
[TBL] [Abstract][Full Text] [Related]
31. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
[TBL] [Abstract][Full Text] [Related]
32. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity.
Griffioen M; van der Meijden ED; Slager EH; Honders MW; Rutten CE; van Luxemburg-Heijs SA; von dem Borne PA; van Rood JJ; Willemze R; Falkenburg JH
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3837-42. PubMed ID: 18316730
[TBL] [Abstract][Full Text] [Related]
33. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Nadal E; Garin M; Kaeda J; Apperley J; Lechler R; Dazzi F
Leukemia; 2007 Mar; 21(3):472-9. PubMed ID: 17215853
[TBL] [Abstract][Full Text] [Related]
34. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.
Tschiedel S; Gentilini C; Lange T; Wölfel C; Wölfel T; Lennerz V; Stevanovic S; Rammensee HG; Huber C; Cross M; Niederwieser D
Leukemia; 2008 Aug; 22(8):1542-50. PubMed ID: 18496563
[TBL] [Abstract][Full Text] [Related]
35. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults.
Barker JN; Davies SM; DeFor TE; Burns LJ; McGlave PB; Miller JS; Weisdorf DJ
Br J Haematol; 2002 Jul; 118(1):101-7. PubMed ID: 12100132
[TBL] [Abstract][Full Text] [Related]
36. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
38. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia.
Jiang YZ; Barrett AJ
Exp Hematol; 1995 Oct; 23(11):1167-72. PubMed ID: 7556526
[TBL] [Abstract][Full Text] [Related]
39. [Autoreactive TCD8+ lymphocytes in patients with chronic myeloid leukemia in association with HLA and adenovirus infection].
Rivera SE; Echeverría M; Salcedo P; Márquez G; Carrillo Z; Parra Y; Cipriani AM; Núñez JR; Álvarez de Mon M; Farruco A
Rev Alerg Mex; 2016; 63(2):163-8. PubMed ID: 27174759
[TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
